Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine.

about

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature.FK506 Attenuates the MRP1-Mediated Chemoresistant Phenotype in Glioblastoma Stem-Like Cells

P2860

Q47167281-BEB7A6B9-8797-467E-A01D-9CE296D8CC73 Q49635346-41A98924-2A9B-4ECC-9C3F-45F791717ECD Q58749539-351216BB-E38D-49A7-A114-9EE369EB4EF9

P2860

Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine.

Item

http://www.wikidata.org/entity/Q40979569

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Bevacizumab as a last-line tre ...... y, temozolomide and lomustine.

@en

type

Item

label

Bevacizumab as a last-line tre ...... y, temozolomide and lomustine.

@en

prefLabel

Bevacizumab as a last-line tre ...... y, temozolomide and lomustine.

@en

P1476

Bevacizumab as a last-line tre ...... py, temozolomide and lomustine

@en

P2093

Emmanouil Fokas

http://www.w3.org/2001/XMLSchema#string

Joachim P Steinbach

http://www.w3.org/2001/XMLSchema#string

Katharina J Wenger

http://www.w3.org/2001/XMLSchema#string

Kea Franz

http://www.w3.org/2001/XMLSchema#string

Marlies Wagner

http://www.w3.org/2001/XMLSchema#string

Martin Voss

http://www.w3.org/2001/XMLSchema#string

Michael C Burger

http://www.w3.org/2001/XMLSchema#string

Oliver Bähr

http://www.w3.org/2001/XMLSchema#string

Se-Jong You

http://www.w3.org/2001/XMLSchema#string

P2860

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

A randomized trial of bevacizumab for newly diagnosed glioblastoma

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review.

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

P304

1141-1146

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2017.6251

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Patrick N. Harter

Michael W Ronellenfitsch

P577

2017-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28693286

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

5494648

http://www.w3.org/2001/XMLSchema#string

Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine.

about

P2860

P2860

Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932